Home » Stocks » ICCC

ImmuCell Corporation (ICCC)

Stock Price: $5.77 USD -0.23 (-3.85%)
Updated December 3, 2:00 PM EST - Market open

Stock Price Chart

Key Info

Market Cap 41.61M
Revenue (ttm) 15.23M
Net Income (ttm) -1.52M
Shares Out 7.21M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $5.77
Previous Close $6.00
Change ($) -0.23
Change (%) -3.85%
Day's Open 5.99
Day's Range 5.74 - 5.89
Day's Volume 6,210
52-Week Range 3.79 - 6.35

More Stats

Market Cap 41.61M
Enterprise Value 45.27M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 7.21M
Float n/a
EPS (basic) -0.21
EPS (diluted) -0.21
FCF / Share -0.44
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3,588
Short Ratio 0.33
Short % of Float n/a
Beta 1.10
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 2.73
PB Ratio 1.50
Revenue 15.23M
Operating Income -988,455
Net Income -1.52M
Free Cash Flow -3.17M
Net Cash -3.66M
Net Cash / Share -0.51
Gross Margin 44.25%
Operating Margin -6.49%
Profit Margin -10.00%
FCF Margin -20.79%
ROA -1.57%
ROE -5.32%
ROIC -3.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$14.00*
Low
14.0
Current: $5.77
High
14.0
Target: 14.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue13.7210.9910.439.5410.237.606.015.395.114.39
Revenue Growth24.91%5.32%9.3%-6.69%34.64%26.46%11.45%5.45%16.53%-
Gross Profit6.745.195.225.426.254.453.063.052.812.30
Operating Income-0.95-1.45-0.240.892.12-0.21-0.020.25-0.63-0.69
Net Income-1.30-2.32-0.170.511.21-0.170.120.09-0.41-0.38
Shares Outstanding6.825.494.954.233.043.033.023.022.982.97
Earnings Per Share-0.19-0.42-0.030.120.38-0.060.040.03-0.14-0.13
EPS Growth----68.42%--33.33%---
Operating Cash Flow0.23-0.371.18-0.222.900.301.100.34-0.04-0.81
Capital Expenditures-0.94-1.78-17.71-3.56-2.65-1.54-0.60-0.28-0.24-0.12
Free Cash Flow-0.71-2.15-16.54-3.780.25-1.230.500.07-0.28-0.93
Cash & Equivalents8.772.523.8010.626.043.345.264.914.964.63
Total Debt8.429.778.963.013.190.901.091.271.440.99
Net Cash / Debt0.35-7.24-5.167.612.862.444.173.653.523.64
Assets38.6932.7334.3024.7014.5411.0510.9611.0310.9910.75
Liabilities9.7010.9910.704.983.931.791.561.841.971.47
Book Value28.9921.7423.5919.7210.619.269.409.199.029.28
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name ImmuCell Corporation
Country United States
Employees 53
CEO Michael Brigham

Stock Information

Ticker Symbol ICCC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ICCC
IPO Date April 30, 1987

Description

ImmuCell Corporation, an animal health company, acquires, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was founded in 1982 and is headquartered in Portland, Maine.